Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

Kwong, Louis M

Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. [electronic resource] - The American journal of managed care Feb 2011 - S22-6 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1936-2692


Anticoagulants--economics
Arthroplasty, Replacement, Hip--adverse effects
Arthroplasty, Replacement, Knee--adverse effects
Cost-Benefit Analysis
Enoxaparin--economics
Factor Xa Inhibitors
Humans
Morpholines--economics
Rivaroxaban
Thiophenes--economics
United States
Venous Thromboembolism--economics